on Theranexus (EPA:ALTHX)
Modification of the Theranexus liquidity contract
On March 6, 2025, Theranexus, a company specializing in the treatment of rare neurological diseases, announced the modification of its liquidity contract with Portzamparc. This approach is part of a desire to comply with AMF decision no. 2018-01 implemented since January 2019.
As part of this amendment, Theranexus withdrew 50,000 euros on the same day. As of the latest balance sheet of December 31, 2024, the liquidity account still showed 110,572 Theranexus shares and a cash balance of 36,223.69 euros.
This revision of the liquidity contract comes in a context where the company must manage a financing horizon limited to Q1 2026, requiring vigilance regarding the impact on shareholder participation and market developments.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news